InMed Pharmaceuticals (INM)
NASDAQ:INM
Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $7.98
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$2.36M
Enterprise Value-$7.53M
Total Cash (Recent Filing)$9.60M
Total Debt (Recent Filing)$730.14K
Price to Earnings (P/E)―
Beta3.37
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-3.19
Enterprise Value/Revenue-1.43
Enterprise Value/Gross Profit-5.38
Enterprise Value/Ebitda0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityA low debt-to-equity profile and consistently positive equity provide durable financial flexibility, reducing default and covenant risk. This strengthens management's ability to fund R&D and regulatory programs via non-debt routes and limits interest burdens that could otherwise squeeze scarce cash resources.
Revenue Growth And Improving Gross MarginSustained top-line expansion with a notable gross margin improvement signals operational progress in commercial or manufacturing capabilities. Higher gross margins suggest the company can better monetize products or inputs, supporting longer-term scalability even while operating losses persist.
Advancing Clinical Programs Toward IND/Phase 1Clear regulatory and development milestones (pre-IND meetings and targeted Phase 1 initiation) materially de-risk candidate progression. Advancing INM-901/INM-089 through IND-enabling work and manufacturing scale-up creates potential durable value catalysts tied to clinical validation rather than short-term market moves.
Bears Say
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flows represent a structural financing challenge: the company must repeatedly access capital markets or strategic partners to fund operations. This increases dilution and constrains long-term R&D runway absent material cash inflows or cost restructuring.
Operating And Net Losses Far Exceed RevenueLosses that materially exceed revenues signal an unsustainable cost structure and negative returns on shareholder capital. Over time this undermines reinvestment capacity and heightens dependence on external financing, making long-term strategy contingent on either rapid clinical success or repeated capital raises.
Exit Of BayMedica Reduces Diversification; Regulatory RiskWinding down BayMedica removes a commercial revenue stream and exposes the company to legislative-driven disruption. The shift concentrates execution risk on early-stage drug programs and increases reliance on successful clinical milestones and external funding to replace lost sales and cover wind-down costs.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $7.98 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $2.36M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 29 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -$0.513 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.513.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.513 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.101%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
13.25%
Insiders
6.91% Other Institutional Investors
79.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---